ArticleGels (Basel, Switzerland)2026
Postoperative Pain Control After Cesarean Section by Continuous Infusion Pump System Versus Ropivacaine Hydrogel: A Prospective Randomized Clinical Trial.
Article in Gels (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThe objective of this study was to evaluate the efficacy of a ropivacaine-loaded poloxamer 407 (P407)-based thermosensitive hydrogel applied at the subfascial site compared with a continuous local anesthetic delivery system using a catheter for postoperative pain control after cesarean section (CS), in combination with standard intravenous patient-controlled analgesia (IV-PCA).
methodsThis single-center, prospective randomized controlled trial included 72 pregnant women undergoing CS between April and October 2025. Participants were randomly assigned to receive either ropivacaine hydrogel or catheter-based ropivacaine infusion, both in conjunction with IV-PCA. Primary outcomes included numeric rating scale (NRS) pain scores at 3, 6, 12, 24, and 48 h postoperatively. Secondary outcomes included the time to first NSAID request and the cumulative use of rescue NSAIDs.
resultsThere were no significant differences in baseline characteristics between the groups. NRS pain scores did not differ significantly at any time point, although they varied significantly over time within each group. The hydrogel group showed a statistically significant delay in the time to first NSAID request (6.3 ± 5.1 h vs. 5.0 ± 6.1 h,
conclusionThe ropivacaine hydrogel provided postoperative pain control comparable to that of the continuous catheter system, with no statistically significant differences in NRS scores observed between groups. Given its ease of use, absence of catheter-related concerns, and substantially lower total anesthetic dose, the P407-based hydrogel may represent a practical and patient-friendly alternative for post-cesarean analgesia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.